BRITNEY KAUFMAN: Open Payments
NPI 1255500724 · ONTARIO, CA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$494 in 25 payments from 7 companies in 2025. Trend: 2023 $419 · 2024 $418 · 2025 $494
Food & beverage: $494
| Company | Payments | Amount |
|---|---|---|
| GENZYME CORPORATION | 9 | $177 |
| UCB, Inc. | 10 | $162 |
| Novartis Pharmaceuticals Corporation | 2 | $45 |
| REVANCE THERAPEUTICS, INC. | 1 | $40 |
| Regeneron Healthcare Solutions, Inc. | 1 | $32 |
| Galderma Laboratories, L.P. | 1 | $22 |
| LNHC, Inc | 1 | $15 |
Products named: DUPIXENT, Bimzelx, DAXXIFY, Rhapsido, DYSPORT, COSENTYX, ZELSUVMI.
Industry payments across CA — which companies pay providers there.
